Citigroup Forecasts Strong Price Appreciation for Royalty Pharma (NASDAQ:RPRX) Stock

07 May 2026, 17:34 by Teresa Graham · The Cerbat Gem

Royalty Pharma (NASDAQ:RPRX – Get Free Report) had its target price boosted by investment analysts at Citigroup from $50.00 to $66.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s target price points to a potential upside of 31.47% from the company’s previous close.

RPRX has been the topic of several other reports. The Goldman Sachs Group reissued a “buy” rating on shares of Royalty Pharma in a report on Thursday, February 12th. Weiss Ratings raised Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, May 1st. Morgan Stanley increased their target price on Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a research note on Friday, April 10th. JPMorgan Chase & Co. lifted their price target on Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Wall Street Zen downgraded Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Seven research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $53.71.

Check Out Our Latest Research Report on Royalty Pharma

Royalty Pharma Stock Performance

Shares of NASDAQ:RPRX traded down $0.52 on Thursday, hitting $50.20. The company had a trading volume of 5,602,082 shares, compared to its average volume of 3,523,412. Royalty Pharma has a 1-year low of $32.15 and a 1-year high of $51.65. The stock has a market cap of $28.96 billion, a price-to-earnings ratio of 37.19, a P/E/G ratio of 3.22 and a beta of 0.40. The stock has a 50 day moving average price of $47.52 and a 200 day moving average price of $42.66. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.88.

Royalty Pharma (NASDAQ:RPRX – Get Free Report) last posted its earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.33 by $0.13. The company had revenue of $621.99 million during the quarter, compared to analysts’ expectations of $839.97 million. Royalty Pharma had a net margin of 32.38% and a return on equity of 28.21%. Analysts expect that Royalty Pharma will post 5.08 EPS for the current year.

Insider Activity at Royalty Pharma

In related news, CFO Terrance P. Coyne sold 34,791 shares of the business’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $49.78, for a total value of $1,731,895.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 139,164 shares of company stock valued at $6,624,902 in the last quarter. 18.84% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Royalty Pharma

Hedge funds have recently bought and sold shares of the company. LM Advisors LLC acquired a new position in shares of Royalty Pharma during the fourth quarter worth $26,000. Lloyd Advisory Services LLC. bought a new stake in Royalty Pharma during the 4th quarter worth $30,000. Smartleaf Asset Management LLC grew its position in Royalty Pharma by 868.1% during the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 790 shares during the last quarter. Private Trust Co. NA increased its holdings in Royalty Pharma by 52.9% in the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 288 shares in the last quarter. Finally, Blue Trust Inc. increased its holdings in Royalty Pharma by 173.4% in the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 437 shares in the last quarter. 54.35% of the stock is owned by institutional investors.

More Royalty Pharma News

Here are the key news stories impacting Royalty Pharma this week:

Positive Sentiment: JPMorgan raised its price target to $58 and upgraded RPRX to “overweight,” implying roughly mid-teens upside from the current quote. Read More.
Positive Sentiment: Company reported Q1 results showing portfolio receipts +10% and royalty receipts +13%, generated $718M of operating cash flow, and raised full‑year 2026 Portfolio Receipts guidance to $3,325M–$3,450M — a clear positive for near‑term revenue visibility. Read More.
Positive Sentiment: Q1 EPS beat consensus ($1.30 reported vs. ~$1.22 expected) and management emphasized confident growth on the earnings call, which supports valuation expectations if receipts continue to ramp. Read More.
Positive Sentiment: Analyst and media writeups flagged an upbeat tone from the Q1 earnings call (management signaling confident growth), reinforcing the bullish interpretation of the quarter. Read More.
Positive Sentiment: Coverage noted RPRX hit a 52‑week high, reflecting strong recent investor interest and momentum into the quarter. Read More.
Neutral Sentiment: Royalty Pharma announced participation in several investor conferences in May, which should increase visibility but is a modest near‑term catalyst. Read More.
Neutral Sentiment: Full Q1 earnings transcripts and call materials are available for deeper review (useful for active investors evaluating guidance and pipeline exposure). Read More. Read More.
Negative Sentiment: Reported revenues for the quarter came in well below some consensus figures cited by analysts (various sources show revenue materially under prior estimates), which could cap upside and explain short‑term selling pressure despite the EPS beat and guidance raise. Read More.

Royalty Pharma Company Profile

(Get Free Report)

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.